Live tape
Top 8, mentions 7d7,424SPCX1,449 mentions▲ +0.09GOOGL1,363 mentions▲ +0.05NVDA1,206 mentions▲ +0.09MSFT853 mentions▲ +0.04QQQ702 mentions▲ +0.08META650 mentions▲ +0.04SPY603 mentions▲ +0.06AMZN598 mentions▲ +0.07

Equity · Healthcare

AMLX

NASDAQ

Amylyx Pharmaceuticals, Inc.

$28.14 +3.42% vs prior close Finazon · prior-day close, indicative (IEX-derived, not the official close) · Oct 9, 2026
Price · Chart
64 sessions
$40 $10 13 Jul 9 Oct

The line runs $17.41 on 13 July through $28.14 on 9 October, on a scale from $10 to $40. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView TradingView chart · our licensed closes: 64 sessions, 13 Jul – 9 Oct 2026
Market cap $3.1B
52-week range $11 – $39.67
Avg volume 90.5K

as of Oct 9, 2026

AMLX insider trades

SEC Form 4

AMLX has no Form 4 filing in the last 90 days, so there is no summary for that window. The most recent filings we hold are below, the newest dated 1 December 2025.

Date Insider Type Shares Value
01 Dec 2025 Bedrosian Camille L Chief Medical Officer Sell 6,580 $94K
30 Sep 2025 FRATES JAMES M Chief Financial Officer Sell 10,558 $155K
30 Sep 2025 Bedrosian Camille L Chief Medical Officer Sell 12,039 $176K
30 Sep 2025 Cohen Joshua B Co-Chief Executive Officer Sell 29,933 $429K
30 Sep 2025 Mazzariello Gina Chief Legal Officer Sell 8,828 $129K
30 Sep 2025 Klee Justin B. Co-Chief Executive Officer Sell 29,975 $431K

AMLX reported financials

SEC EDGAR XBRL SEC EDGAR

AMLX reported revenue of $0 for the fiscal year ended 31 Dec 2025. Net income over the same period was −$144.7M.

Figure Reported Period
Revenue $0 31 Dec 2025 fiscal year
Net income −$144.7M 31 Dec 2025 fiscal year
Diluted EPS −$1.53 31 Dec 2025 fiscal year
Total assets $264.6M 30 Jun 2026 at period end
Total equity $239.2M 30 Jun 2026 at period end

AMLX earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 −$0.39 —
31 Mar 2026 Q1 2026 −$0.37 —
31 Dec 2025 FY 2025 −$1.53 —
30 Sep 2025 Q3 2025 −$0.37 —
30 Jun 2025 Q2 2025 −$0.46 —
31 Mar 2025 Q1 2025 −$0.42 —
31 Dec 2024 FY 2024 −$4.43 —
30 Sep 2024 Q3 2024 −$1.07 —

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

AMLX institutional holders

SEC Form 13F SEC EDGAR

6 of the 45 institutional funds we track reported a AMLX position for the quarter ended 30 Jun 2026 — a combined $30.3M; the latest of those filings landed 02 Sep 2026.

Fund Action Shares Value
Balyasny Asset Management Trimmed −38.1% shares 684,974 $12.3M
Two Sigma Investments Added +266.4% shares 593,435 $10.7M
Citadel Advisors Trimmed −56.6% shares 178,686 $3.2M
D. E. Shaw & Co. Added +134.8% shares 174,285 $3.1M
Tudor Investment Corp Held (±25%) +13.0% shares 35,410 $636K
AQR Capital Management Trimmed −28.4% shares 20,819 $374K
Point72 Asset Management Exited

AMLX fails-to-deliver

SEC CNS data SEC

On 31 Aug 2026, 1 shares of AMLX failed to deliver (about $35).

Settlement date Shares failed Notional % of shares out
31 Aug 2026 1 $35 <0.001%

Congressional trades in AMLX

STOCK Act disclosures House disclosures

The most recent congressional trade disclosed in AMLX is a purchase by Sara Jacobs (house, CA), dated 12 Oct 2022.

Date Member Type Amount
12 Oct 2022 filed 16 Nov 2022 Sara Jacobs house · Democrat–CA Purchase $1K–$15K

Sources

  1. Finazonprior-day close, indicative (IEX-derived, not the official close), most closes dollar-rounded at the source
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARSEC EDGAR XBRL company facts · latest period ended 30 Jun 2026
  4. SEC EDGARSEC EDGAR 13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. House disclosuresU.S. House of Representatives financial disclosures
  7. SEC EDGARValuation computed from SEC EDGAR filings